Arcus Biosciences (RCUS) Q2 2026 Earnings Report

The call emphasized multiple substantial clinical and business positives: strong translational validation (Nature paper), robust development progress for casdatifan with clear registrational timelines (PEAK‑1 enrollment on track and PEAK‑20 planned), multiple strategic collaborations, a broad immunology pipeline with near‑term IND milestones (AB102, TNFR1), and a solid cash runway into H2 2028. Key near‑term risks include a meaningful quarter‑over‑quarter cash reduction (~11.5%), expected declines in collaboration revenue from the Gilead wind‑down, high R&D spend with planned concentration (>80%) on casdatifan by 2027, and dependence on upcoming clinical readouts to validate the growth and revenue thesis. On balance, the highlights — clinical progress, partnerships, translational evidence, and adequate runway — outweigh the lowlights, which are primarily financial/timing and execution risks.

Management provided specific near- and medium-term guidance: as of June 30, 2026 Arcus had $775M cash and investments (down from $876M at March 31), expects to end 2026 with ~ $600M and to have runway into at least H2 2028; Q2 GAAP revenue was $41M with full-year 2026 GAAP revenue guided to $65–75M; Q2 R&D expense was $113M (net) with R&D expected to meaningfully decline in 2026–27 and >80% of 2027 portfolio spend directed to casdatifan, G&A was $24M and non-cash stock‑based comp $15M in Q2. Clinical and commercial timelines: PEAK‑1 (cas + cabozantinib) remains on track to complete enrollment by year‑end 2026, PEAK‑20 (first‑line registrational trial) to start by year‑end 2026, ARC‑20 will deliver a broad October data package from >200 patients (including a first‑line cas+zim cohort with 30 patients and a 7% primary progression rate, a cas+zim ORR readout with ~11 months follow‑up, a second‑line cas+cabo cohort of ~45 patients with ≥18 months follow‑up, and ~120 late‑line monotherapy patients with ~28 months median follow‑up), PRISM‑1 (quemliclustat in pancreatic cancer) is expected to read out in H1 next year, AB102 dosing begins this month with PK data in Q4 and a TNFR1 program entering clinic in early 2027. Finally, market and value context: Arcus projects RCC sales in major markets to reach ~$13B by 2030, estimates PEAK‑1 addresses ~20,000 IO‑experienced patients (> $2B opportunity), first‑line > $4B, and total peak sales opportunity for casdatifan of $5–10B.